The September/October issue of NeuroPerspective has been released. It features our comprehensive annual review of the Alzheimer’s space, including an assessment of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets. Aducanumab has somehow survived at the head of the regulatory menu, its prospects are discussed at length. Despite the early disappointments in PSP, tau therapeutics are now in the spotlight as they begin to produce data. The neuroimmunological space has started to mature, with clinical stage programs underway from Denali/Sanofi and Alector/AbbVie, and this type of midstream focus offers the prospect of disease modification without having to precisely identify the upstream molecular culprit that initiates the disease process. Cortexyme will have an interim analysis in the next few months that will give a first look at the potential impact of this infection-based paradigm.
Among the 200+ programs assessed are those from: AbbVie/Alector, AC Immune, Alkahest, Anavex, Athira, Axon-Neuroscience, Biogen, Cognition Therapeutics, Cortexyme, Denali, Eisai, EIP Pharma, Grifols, Lilly, Oryzon, Roche, Syndesi, TauRx, and Voyager. Sidebars include coverage of the current state of the AD Biomarker art and an overview of the POC timelines for major AD programs.
The issue also includes a full review of Frontotemporal Dementia (FTD), including a breakdown of the complex heterogeneity within this umbrella category, with marked divergences in genotype and phenotypic signs. FTD-PGRN has emerged as a particular subset of interest, with progranulin enhancing programs in development by Alector, Arkuda, Passage Bio, and Prevail, amongst several.
The September/October issue includes a focused review of Prevail Therapeutics as well as coverage of the extremely busy funding and partnering season, which has seen a number of companies taking diverse routes to the public markets, including Cerevel, Harmony Biosciences, and Yumanity, with Compass Pathways and Athira Pharma on the runway.